Details of the Drug

General Information of Drug (ID: DMCFE9I)

Drug Name

Valproate

Synonyms

99-66-1; Dipropylacetic acid; Depakine; Depakene; 2-Propylvaleric acid; Ergenyl; Di-n-propylacetic acid; Mylproin; Pentanoic acid, 2-propyl-; 4-Heptanecarboxylic acid; Propylvaleric acid; n-Dipropylacetic acid; Myproic Acid; Di-n-propylessigsaure; n-DPA; Dipropylacetate; Convulex; Depakin; Vupral; Acido valproico; Acide valproique; Acidum valproicum; Stavzor; Avugane; Baceca; Kyselina 2-propylvalerova; 2-n-Propyl-n-valeric acid; Acetic acid, dipropyl-; Abbott 44090; Valproinsaeure; Savicol; Convulsofin; Deproic; VPA; Depakin chrono; Dipropyl Acetate; Med Valproic; Valproic acid USP; Valproic acid USP24; Acide valproique [INN-French]; Acido valproico [INN-Spanish]; Acidum valproicum [INN-Latin]; Alti-Valproic; Depakote (TM); Dom-Valproic; G2M-777; Kyselina 2-propylvalerova [Czech]; N-DPA; N-Dipropylacetic acid; Novo-Valproic; Nu-Valproic; PMS-Valproic Acid; Penta-Valproic; Valproic acid (USP); Di-n-propylessigsaeure; Di-n-propylessigsaure [German]; Valproic acid [USAN:INN:BAN]; Valproic Acid, SodiumSalt (2:1); 2 PP (base)

Indication

Disease Entry	ICD 11	Status	REF
Epilepsy	8A60-8A68	Approved	[1]
Alcohol dependence	6C40.2	Phase 2	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Neurology Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

144.21

Logarithm of the Partition Coefficient (xlogp)

2.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: 99% of drug becomes completely available to its intended biological destination(s) [4]
Clearance: The drug present in the plasma can be removed from the body at the rate of 0.16 mL/min/kg [5]
Elimination: 1.8% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 12 hours [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 289.15057 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.08% [5]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.14 L/kg [5]
Water Solubility: The ability of drug to dissolve in water is measured as 1.3 mg/mL [3]

Chemical Identifiers

Formula: C8H16O2
IUPAC Name: 2-propylpentanoic acid
Canonical SMILES: CCCC(CCC)C(=O)O
InChI: InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
InChIKey: NIJJYAXOARWZEE-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3121
ChEBI ID: CHEBI:39867
CAS Number: 99-66-1
DrugBank ID: DB00313
TTD ID: D0Y3KG
VARIDT ID: DR00399
INTEDE ID: DR1667
ACDINA ID: D00717

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glycogen synthase kinase-3 alpha (GSK-3A)	TTRZQE3	GSK3A_HUMAN	Inhibitor	[2]
Histone deacetylase (HDAC)	TTBH0VX	NOUNIPROTAC	Inhibitor	[7]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Monocarboxylate transporter 2 (SLC16A7)	DTLT3UG	MOT2_HUMAN	Substrate	[8]
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[10]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[11]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[10]
Cytochrome P450 2A6 (CYP2A6)	DEJVYAZ	CP2A6_HUMAN	Substrate	[12]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[13]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[14]
UDP-glucuronosyltransferase 2B7 (UGT2B7)	DEB3CV1	UD2B7_HUMAN	Substrate	[15]
Prostaglandin G/H synthase 1 (COX-1)	DE073H6	PGH1_HUMAN	Substrate	[13]
UDP-glucuronosyltransferase 1A9 (UGT1A9)	DE85D2P	UD19_HUMAN	Substrate	[13]
UDP-glucuronosyltransferase 1A10 (UGT1A10)	DEL5N6Y	UD110_HUMAN	Substrate	[16]
UDP-glucuronosyltransferase 1A6 (UGT1A6)	DESD26P	UD16_HUMAN	Substrate	[16]
UDP-glucuronosyltransferase 1A3 (UGT1A3)	DEF2WXN	UD13_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
(3R)-3-hydroxyacyl-CoA dehydrogenase (HSD17B8)	OTX1DWEF	DHB8_HUMAN	Gene/Protein Processing	[17]
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1)	OTG2T749	CP24A_HUMAN	Gene/Protein Processing	[18]
1,4-alpha-glucan-branching enzyme (GBE1)	OTK2N05B	GLGB_HUMAN	Gene/Protein Processing	[19]
1,5-anhydro-D-fructose reductase (AKR1E2)	OT7GBQEB	AKCL2_HUMAN	Post-Translational Modifications	[20]
1-acyl-sn-glycerol-3-phosphate acyltransferase beta (AGPAT2)	OT5I4Y9K	PLCB_HUMAN	Gene/Protein Processing	[21]
1-acyl-sn-glycerol-3-phosphate acyltransferase delta (AGPAT4)	OT5CTQKO	PLCD_HUMAN	Gene/Protein Processing	[19]
1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon (AGPAT5)	OTNY3VMD	PLCE_HUMAN	Post-Translational Modifications	[20]
1-acyl-sn-glycerol-3-phosphate acyltransferase gamma (AGPAT3)	OTAUR5TG	PLCC_HUMAN	Post-Translational Modifications	[20]
1-acylglycerol-3-phosphate O-acyltransferase ABHD5 (ABHD5)	OTY829Z3	ABHD5_HUMAN	Gene/Protein Processing	[22]
1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 (PNPLA3)	OTR4990X	PLPL3_HUMAN	Post-Translational Modifications	[20]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Valproate

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Primidone	DM0WX6I	Moderate	Decreased metabolism of Valproate caused by Primidone mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[23]
Mephenytoin	DM5UGDK	Moderate	Increased plasma concentration of Valproate and Mephenytoin due to competitive binding of plasma proteins.	Epilepsy/seizure [8A61-8A6Z]	[24]
Tiagabine	DMKSQG0	Minor	Increased plasma concentration of Valproate and Tiagabine due to competitive binding of plasma proteins.	Epilepsy/seizure [8A61-8A6Z]	[25]
Fosphenytoin	DMOX3LB	Moderate	Increased plasma concentration of Valproate and Fosphenytoin due to competitive binding of plasma proteins.	Epilepsy/seizure [8A61-8A6Z]	[23]
Ethotoin	DMXWOCP	Moderate	Increased plasma concentration of Valproate and Ethotoin due to competitive binding of plasma proteins.	Epilepsy/seizure [8A61-8A6Z]	[24]
-----------

Coadministration of a Drug Treating the Disease Different from Valproate (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Valproate and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[26]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Valproate caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[27]
Nifedipine	DMSVOZT	Moderate	Decreased metabolism of Valproate caused by Nifedipine mediated interference with first-pass metabolism.	Angina pectoris [BA40]	[28]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Valproate and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[29]
Montelukast	DMD157S	Moderate	Decreased metabolism of Valproate caused by Montelukast mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[30]
Desipramine	DMT2FDC	Moderate	Antagonize the effect of Valproate when combined with Desipramine.	Attention deficit hyperactivity disorder [6A05]	[31]
Lamotrigine	DM8SXYG	Major	Decreased metabolism of Valproate caused by Lamotrigine mediated inhibition of UGT.	Bipolar disorder [6A60]	[32]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Valproate and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[33]
Nitazoxanide	DMOWLVG	Moderate	Increased plasma concentration of Valproate and Nitazoxanide due to competitive binding of plasma proteins.	Bowel habit change [ME05]	[34]
Levomilnacipran	DMV26S8	Moderate	Antagonize the effect of Valproate when combined with Levomilnacipran.	Chronic pain [MG30]	[35]
Anisindione	DM2C48U	Moderate	Increased plasma concentration of Valproate and Anisindione due to competitive binding of plasma proteins.	Coagulation defect [3B10]	[36]
Regorafenib	DMHSY1I	Moderate	Decreased metabolism of Valproate caused by Regorafenib mediated inhibition of UGT.	Colorectal cancer [2B91]	[37]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Valproate and Olopatadine.	Conjunctiva disorder [9A60]	[38]
Nimodipine	DMQ0RKZ	Minor	Decreased metabolism of Valproate caused by Nimodipine mediated interference with first-pass metabolism.	Coronary vasospastic disease [BA85]	[39]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Valproate and Ethanol.	Cystitis [GC00]	[38]
Sertraline	DM0FB1J	Moderate	Antagonize the effect of Valproate when combined with Sertraline.	Depression [6A70-6A7Z]	[35]
Trimipramine	DM1SC8M	Moderate	Additive CNS depression effects by the combination of Valproate and Trimipramine.	Depression [6A70-6A7Z]	[31]
Imipramine	DM2NUH3	Moderate	Additive CNS depression effects by the combination of Valproate and Imipramine.	Depression [6A70-6A7Z]	[31]
Fluoxetine	DM3PD2C	Minor	Decreased metabolism of Valproate caused by Fluoxetine.	Depression [6A70-6A7Z]	[40]
Nortriptyline	DM4KDYJ	Moderate	Additive CNS depression effects by the combination of Valproate and Nortriptyline.	Depression [6A70-6A7Z]	[31]
Vilazodone	DM4LECQ	Moderate	Antagonize the effect of Valproate when combined with Vilazodone.	Depression [6A70-6A7Z]	[35]
Paroxetine	DM5PVQE	Moderate	Increased risk of hyponatremia by the combination of Valproate and Paroxetine.	Depression [6A70-6A7Z]	[35]
Vortioxetine	DM6F1PU	Moderate	Increased risk of hyponatremia by the combination of Valproate and Vortioxetine.	Depression [6A70-6A7Z]	[35]
Duloxetine	DM9BI7M	Moderate	Increased risk of hyponatremia by the combination of Valproate and Duloxetine.	Depression [6A70-6A7Z]	[35]
Milnacipran	DMBFE74	Moderate	Antagonize the effect of Valproate when combined with Milnacipran.	Depression [6A70-6A7Z]	[35]
Escitalopram	DMFK9HG	Moderate	Increased risk of hyponatremia by the combination of Valproate and Escitalopram.	Depression [6A70-6A7Z]	[35]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of hyponatremia by the combination of Valproate and Desvenlafaxine.	Depression [6A70-6A7Z]	[35]
Amitriptyline	DMK7F9S	Moderate	Additive CNS depression effects by the combination of Valproate and Amitriptyline.	Depression [6A70-6A7Z]	[31]
Amoxapine	DMKITQE	Moderate	Antagonize the effect of Valproate when combined with Amoxapine.	Depression [6A70-6A7Z]	[31]
Protriptyline	DMNHTZI	Moderate	Antagonize the effect of Valproate when combined with Protriptyline.	Depression [6A70-6A7Z]	[31]
Doxepin	DMPI98T	Moderate	Additive CNS depression effects by the combination of Valproate and Doxepin.	Depression [6A70-6A7Z]	[31]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Valproate and Esketamine.	Depression [6A70-6A7Z]	[26]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Valproate and Cannabidiol.	Epileptic encephalopathy [8A62]	[27]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Valproate and Brimonidine.	Glaucoma [9C61]	[41]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Valproate and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[42]
Zidovudine	DM4KI7O	Moderate	Decreased metabolism of Valproate caused by Zidovudine mediated inhibition of UGT.	Human immunodeficiency virus disease [1C60-1C62]	[43]
Efavirenz	DMC0GSJ	Moderate	Increased risk of hepatotoxicity by the combination of Valproate and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[44]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Valproate caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[45]
Ritonavir	DMU764S	Moderate	Increased metabolism of Valproate caused by Ritonavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[26]
Fenofibrate	DMFKXDY	Moderate	Decreased metabolism of Valproate caused by Fenofibrate mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[26]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Valproate and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[46]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Valproate and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[28]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Valproate and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[47]
Lesinurad	DMUR64T	Moderate	Decreased metabolism of Valproate caused by Lesinurad mediated inhibition of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[48]
Methotrexate	DM2TEOL	Moderate	Increased risk of hepatotoxicity by the combination of Valproate and Methotrexate.	Leukaemia [2A60-2B33]	[27]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Valproate caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[26]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Valproate caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[26]
Chloroquine	DMSI5CB	Moderate	Antagonize the effect of Valproate when combined with Chloroquine.	Malaria [1F40-1F45]	[26]
Hydroxychloroquine	DMSIVND	Moderate	Antagonize the effect of Valproate when combined with Hydroxychloroquine.	Malaria [1F40-1F45]	[26]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Valproate and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[49]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Valproate and Idelalisib.	Mature B-cell leukaemia [2A82]	[50]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Valproate and Clofarabine.	Mature B-cell lymphoma [2A85]	[51]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Valproate due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[26]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Valproate and Lasmiditan.	Migraine [8A80]	[52]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Valproate due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[28]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Valproate and Flibanserin.	Mood disorder [6A60-6E23]	[53]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Valproate and Thalidomide.	Multiple myeloma [2A83]	[54]
Orlistat	DMRJSP8	Moderate	Altered absorption of Valproate caused by Orlistat.	Obesity [5B80-5B81]	[55]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Valproate caused by Rucaparib mediated inhibition of UGT.	Ovarian cancer [2C73]	[56]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Valproate and Dextropropoxyphene.	Pain [MG30-MG3Z]	[57]
Diflunisal	DM7EN8I	Moderate	Increased plasma concentration of Valproate and Diflunisal due to competitive binding of plasma proteins.	Pain [MG30-MG3Z]	[58]
Ibuprofen	DM8VCBE	Minor	Increased plasma concentration of Valproate and Ibuprofen due to competitive binding of plasma proteins.	Pain [MG30-MG3Z]	[59]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Valproate and Buprenorphine.	Pain [MG30-MG3Z]	[60]
Meperidine	DMX4GND	Moderate	Additive CNS depression effects by the combination of Valproate and Meperidine.	Pain [MG30-MG3Z]	[61]
Esomeprazole	DM7BN0X	Minor	Increased plasma concentrations of Valproate and Esomeprazole due to competitive inhibition of the same metabolic pathway.	Peptic ulcer [DA61]	[62]
Choline salicylate	DM8P137	Moderate	Increased plasma concentration of Valproate and Choline salicylate due to competitive binding of plasma proteins.	Postoperative inflammation [1A00-CA43]	[58]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Valproate caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[63]
Selexipag	DMAHSU0	Moderate	Decreased metabolism of Valproate caused by Selexipag mediated inhibition of UGT.	Pulmonary hypertension [BB01]	[26]
Salsalate	DM13P4C	Moderate	Increased plasma concentration of Valproate and Salsalate due to competitive binding of plasma proteins.	Rheumatoid arthritis [FA20]	[58]
Celecoxib	DM6LOQU	Moderate	Decreased metabolism of Valproate caused by Celecoxib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[64]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Valproate and Leflunomide.	Rheumatoid arthritis [FA20]	[28]
Paliperidone	DM7NPJS	Moderate	Additive CNS depression effects by the combination of Valproate and Paliperidone.	Schizophrenia [6A20]	[27]
Risperidone	DMN6DXL	Moderate	Increased plasma concentration of Valproate and Risperidone due to competitive binding of plasma proteins.	Schizophrenia [6A20]	[65]
Salicyclic acid	DM2F8XZ	Moderate	Increased plasma concentration of Valproate and Salicyclic acid due to competitive binding of plasma proteins.	Seborrhoeic dermatitis [EA81]	[66]
Vardenafil	DMTBGW8	Moderate	Decreased metabolism of Valproate caused by Vardenafil mediated inhibition of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[67]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Valproate and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[27]
Epirubicin	DMPDW6T	Moderate	Increased risk of hepatotoxicity by the combination of Valproate and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[26]
Pitolisant	DM8RFNJ	Moderate	Accelerated clearance of Valproate due to the transporter induction by Pitolisant.	Somnolence [MG42]	[27]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Valproate and Naltrexone.	Substance abuse [6C40]	[68]
Warfarin	DMJYCVW	Moderate	Increased plasma concentration of Valproate and Warfarin due to competitive binding of plasma proteins.	Supraventricular tachyarrhythmia [BC81]	[36]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Valproate due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[56]
Cetirizine	DMOMP9U	Moderate	Additive CNS depression effects by the combination of Valproate and Cetirizine.	Vasomotor/allergic rhinitis [CA08]	[69]
-----------


⏷ Show the Full List of 82 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 27	E00381	83511	Colorant
D&C red no. 28	E00491	6097185	Colorant
D&C red no. 30	E00456	3000709	Colorant
Diethyl phthalate	E00135	6781	Plasticizing agent; Solvent
Ethyl acrylate	E00191	8821	Film/membrane-forming agent; Flavoring agent
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Hydrazine yellow	E00409	164825	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
methylparaben	E00149	7456	Antimicrobial preservative
Oleic acid	E00421	445639	Emulsifying agent; Penetration agent; Solubilizing agent
Phenoxyisopropanol	E00386	92839	Antimicrobial preservative
Propyl 4-hydroxybenzoate	E00141	7175	Antimicrobial preservative
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Vanillin	E00049	1183	Flavoring agent
Acetone	E00004	180	Solvent
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Dibutyl sebacate	E00160	7986	Plasticizing agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Glyceryl behenate	E00481	5362585	Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Glyceryl dibehenate	E00537	22477175	Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Hypromellose	E00634	Not Available	Coating agent
Isobutyl alcohol	E00130	6560	Flavoring agent; Solvent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium hydroxide	E00233	14797	Alkalizing agent
Potassium sorbate	E00566	23676745	Antimicrobial preservative
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate	E00424	516892	Alkalizing agent; Diluent
Sodium hydroxide	E00234	14798	Alkalizing agent
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 59 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Valproic acid 250 mg tablet	250 mg	Delayed Release Oral Tablet	Oral
Valproic acid 500 mg tablet	500 mg	Delayed Release Oral Tablet	Oral
Valproic acid 125 mg tablet	125 mg	Delayed Release Oral Tablet	Oral
Valproic acid 125 mg capsule	125 mg	Delayed Release Oral Capsule	Oral
Valproic acid 125 mg tablet	125 mg	Delayed Release Tablet	Oral
Valproic acid 125 mg tablet	125 mg	Enteric Coated Tablet	Oral
Valproic acid 500 mg tablet	500 mg	Enteric Coated Tablet	Oral
Valproic acid 250 mg tablet	250 mg	24 HR Extended Release Tablet	Oral
Valproic acid 500 mg tablet	500 mg	24 HR Extended Release Tablet	Oral
Valproic acid 250 mg tablet	250 mg	Enteric Coated Tablet	Oral
Valproic acid 250 mg tablet	250 mg	24 HR Extended Release Oral Tablet	Oral
Valproic acid 500 mg tablet	500 mg	24 HR Extended Release Oral Tablet	Oral
Valproic acid 500 mg tablet	500 mg	Delayed Release Tablet	Oral
Valproic acid 250 mg capsule	250 mg	Delayed Release Oral Capsule	Oral
Valproic acid 500 mg capsule	500 mg	Delayed Release Oral Capsule	Oral
Valproic acid 250 mg capsule	250 mg	Oral Capsule	Oral
Valproic acid 250 mg tablet	250 mg	Delayed Release Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7009).
2	Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. Expert Opin Ther Targets. 2008 Nov;12(11):1367-76.
3	BDDCS applied to over 900 drugs
4	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086.
8	Monocarboxylate Transporters in Drug Disposition: Role in the Toxicokinetics and Toxicodynamics of the Drug of Abuse GHB.
9	Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol. 2010 Feb;44(2):152-67.
10	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
11	Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
12	Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
13	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
14	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
15	Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
16	UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther. 2005 Jun;313(3):1340-6.
17	The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
18	Valproic acid augments vitamin D receptor-mediated induction of CYP24 by vitamin D3: a possible cause of valproic acid-induced osteomalacia?. Toxicol Lett. 2011 Feb 5;200(3):146-53. doi: 10.1016/j.toxlet.2010.11.008. Epub 2010 Nov 27.
19	Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
20	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
21	Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
22	In vitro assessment of drug-induced liver steatosis based on human dermal stem cell-derived hepatic cells. Arch Toxicol. 2016 Mar;90(3):677-89. doi: 10.1007/s00204-015-1483-z. Epub 2015 Feb 26.
23	Bourgeois BF "Pharmacologic interactions between valproate and other drugs." Am J Med 84 (1988): 29-33. [PMID: 3146222]
24	Henriksen O, Johannessen SI "Clinical and pharmacokinetic observations on sodium valproate: a 5-year follow-up study in 100 children with epilepsy." Acta Neurol Scand 65 (1982): 504-23. [PMID: 6810648]
25	Product Information. Gabitril (tiagabine). Abbott Pharmaceutical, Abbott Park, IL.
26	Cerner Multum, Inc. "Australian Product Information.".
27	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
28	Canadian Pharmacists Association.
29	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
30	Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT "Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast." Clin Pharmacol Ther (2010):. [PMID: 20592724]
31	Fu C, Katzman M, Goldbloom DS "Valproate/nortriptyline interaction." J Clin Psychopharmacol 14 (1994): 205-6. [PMID: 8027418]
32	Anderson GD, Yau MK, Gidal BE, Harris SJ, Levy RH, Lai AA, Wolf KB, Wargin WA, Dren AT "Bidirectional interaction of valproate and lamotrigine in healthy subjects." Clin Pharmacol Ther 60 (1996): 145-56. [PMID: 8823232]
33	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
34	Product Information. Alinia (nitazoxanide). Romark Laboratories L.C., Tampa, FL.
35	Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
36	Guthrie SK, Stoysich AM, Bader G, Hilleman DE "Hypothesized interaction between valproic acid and warfarin." J Clin Psychopharmacol 15 (1995): 138-9. [PMID: 7782487]
37	Product Information. Stivarga (regorafenib). Bayer Pharmaceutical Inc, West Haven, CT.
38	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
39	Tartara A, Galimberti CA, Manni R, et al "Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients." Br J Clin Pharmacol 32 (1991): 335-40. [PMID: 1777370]
40	Corrigan FM "Sodium valproate augmentation of fluoxetine or fluvoxamine effects." Biol Psychiatry 31 (1992): 1178-9. [PMID: 1525286]
41	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
42	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
43	Lertora JJ, Rege AB, Greenspan DL, et al "Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus." Clin Pharmacol Ther 56 (1994): 272-8. [PMID: 7924122]
44	Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
45	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
46	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
47	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
48	Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
49	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
50	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
51	Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
52	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
53	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
54	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
55	Bigham S, McGuigan C, MacDonald BK "Reduced absorption of lipophilic anti-epileptic medications when used concomitantly with the anti-obesity drug orlistat." Epilepsia 47 (2006): 2207. [PMID: 17201727]
56	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
57	Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
58	Abbott FS, Kassam J, Orr JM, Farrell K "The effect of aspirin on valproic acid metabolism." Clin Pharmacol Ther 40 (1986): 94-100. [PMID: 3087680]
59	Dasgupta A, Volk A "Displacement of valproic acid and carbamazepine from protein binding in normal and uremic sera by tolmetin, ibuprofen, and naproxen: presence of inhibitor in uremic serum that blocks valproic acid-naproxen interactions." Ther Drug Monit 18 (1996): 284-7. [PMID: 8738769]
60	Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
61	Lambertsen CJ, Wendel H, Longenhagen JB "The separate and combined respiratory effects of chlorpromazine and meperidine in normal men controlled at 46 mm Hg alveolar pCO2." J Pharmacol Exp Ther 131 (1961): 381-93. [PMID: 13758472]
62	Product Information. Nexium (esomeprazole) Astra-Zeneca Pharmaceuticals, Wilmington, DE.
63	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
64	Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
65	Baldassano CF, Ghaemi SN "Generalized edema with risperidone: divalproex sodium treatment." J Clin Psychiatry 57 (1996): 422. [PMID: 9746451]
66	Dasgupta A, Jacques M "Reduced in vitro displacement of valproic acid from protein binding by salicylate in uremic sera compared with normal sera - role of uremic compounds." Am J Clin Pathol 101 (1994): 349-53. [PMID: 8135194]
67	Product Information. Levitra (vardenafil). Bayer, West Haven, CT.
68	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
69	Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.